Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2022;2453:79–89. doi: 10.1007/978-1-0716-2115-8_5

Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR.

Irene Della Starza, Cornelia Eckert, Daniela Drandi, Giovanni Cazzaniga; EuroMRD Consortium
PMCID: PMC9761497  PMID: 35622321

Abstract

Analysis of immunoglobulin and T-cell receptor gene rearrangements by real-time quantitative polymerase chain reaction (RQ-PCR) is the gold standard for sensitive and accurate minimal residual disease (MRD) monitoring; it has been extensively standardized and guidelines have been developed within the EuroMRD consortium ( www.euromrd.org ). However, new generations of PCR-based methods are standing out as potential alternatives to RQ-PCR, such as digital PCR technology (dPCR), the third-generation implementation of conventional PCR, which has the potential to overcome some of the limitations of RQ-PCR such as allowing the absolute quantification of nucleic acid targets without the need for a calibration curve. During the last years, droplet digital PCR (ddPCR) technology has been compared to RQ-PCR in several hematologic malignancies showing its proficiency for MRD analysis. So far, no established guidelines for ddPCR MRD analysis and data interpretation have been defined and its potential is still under investigation. However, a major standardization effort is underway within the EuroMRD consortium ( www.euromrd.org ) for future application of ddPCR in standard clinical practice.

Full text of this article can be found in Bookshelf.

References

  1. Cazzaniga G, Biondi A (2005) Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 90:382–390 [PubMed]
  2. Faderl S, O’Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D et al (2010) Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116:1165–1176 doi: 10.1002/cncr.24862. [DOI] [PMC free article] [PubMed]
  3. Gökbuget N, Raff R, Brüggemann M, Flohr T, Scheuring U, Pfeifer H et al (2004) Risk/MRD adapted GMALL trials in adult ALL. Ann Hematol 83:S129–S131 doi: 10.1007/s00277-004-0850-2. [DOI] [PubMed]
  4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206–3214 doi: 10.1182/blood-2009-10-248146. [DOI] [PubMed]
  5. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R et al (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 14:199–109 doi: 10.1016/S1470-2045(12)70600-9. [DOI] [PubMed]
  6. Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R et al (2013) Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 31:2736–2742 doi: 10.1200/JCO.2012.48.5680. [DOI] [PubMed]
  7. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E et al (2016) Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group. J Clin Oncol 34:2591–2501 doi: 10.1200/JCO.2015.64.6364. [DOI] [PubMed]
  8. Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA et al (2019) Minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol 9:689 doi: 10.3389/fonc.2019.00689. [DOI] [PMC free article] [PubMed]
  9. Landgren O, Lu SX, Hultcrantz M (2018) MRD testing in multiple myeloma: the Main future driver for modern tailored treatment. Semin Hematol 55(1):44–50 doi: 10.1053/j.seminhematol.2018.03.001. [DOI] [PubMed]
  10. Pott C, Brüggemann M, Ritgen M, van der Velden VHJ, van Dongen JJM, Kneba M (2019) MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol 1956:199–228 doi: 10.1007/978-1-4939-9151-8_9. [DOI] [PubMed]
  11. Van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al (2007) European study group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604–611 doi: 10.1038/sj.leu.2404586. [DOI] [PubMed]
  12. Huggett JF, Whale A (2013) Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem 59:1691–1693 doi: 10.1373/clinchem.2013.214742. [DOI] [PubMed]
  13. Sanders R, Huggett JF, Bushell CA, Cowen S, Scott DJ, Foy CA (2011) Evaluation of digital PCR for absolute DNA quantification. Anal Chem 83:6474–6484 doi: 10.1021/ac103230c. [DOI] [PubMed]
  14. Vincent ME, Liu W, Haney EB, Ismagilov RF (2010) Microfluidic stochastic confinement enhances analysis of rare cells by isolating cells and creating high density environments for control of diffusible signals. Chem Soc Rev 39:974–984 doi: 10.1039/b917851a. [DOI] [PMC free article] [PubMed]
  15. Stahl T, Böhme MU, Kröger N, Fehse B (2015) Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. Exp Hematol 43:462–468 doi: 10.1016/j.exphem.2015.02.006. [DOI] [PubMed]
  16. Drandi D, Kubiczkova-Besse L, Ferrero S et al (2015) Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn 17(6):652–660 doi: 10.1016/j.jmoldx.2015.05.007. [DOI] [PubMed]
  17. Della Starza I, Nunes V, Cavalli M et al (2016) Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic Leukaemia. Br J Haematol 174(4):541–549 doi: 10.1111/bjh.14082. [DOI] [PubMed]
  18. Cavalli M, De Novi LA, Della Starza I, Cappelli LV, Nunes V, Pulsoni A et al (2017) Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. Br J Haematol 177:588–596 doi: 10.1111/bjh.14616. [DOI] [PubMed]
  19. Coccaro N, Anelli L, Zagaria A, Casieri P, Tota G, Orsini P et al (2018) Droplet digital PCR is a robust tool for monitoring minimal residual disease in adult Philadelphia-positive acute lymphoblastic leukemia. J Mol Diagn 20:474–482 doi: 10.1016/j.jmoldx.2018.03.002. [DOI] [PubMed]
  20. Drandi D, Ferrero S, Ladetto. (2018) Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders. Methods Mol Biol 1768:229–256 doi: 10.1007/978-1-4939-7778-9_14. [DOI] [PubMed]
  21. Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G et al (2020) Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL network. Hemasphere 4(2):e347 doi: 10.1097/HS9.0000000000000347. [DOI] [PMC free article] [PubMed]
  22. Della Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A et al (2021) Droplet digital PCR improves IG−/TR-based MRD risk definition in childhood B-cell precursor acute lymphoblastic leukemia. Hemasphere 5(3):e543 doi: 10.1097/HS9.0000000000000543. [DOI] [PMC free article] [PubMed]
  23. Cazzaniga G, Songia S, Biondi A, EuroMRD Working Group (2021) PCR technology to identify minimal residual disease. Methods Mol Biol 2185:77–94 doi: 10.1007/978-1-0716-0810-4_6. [DOI] [PubMed]
  24. Kotrova M, Darzentas N, Pott C, Brüggemann M, EuroClonality-NGS Working Group (2021) Next-generation sequencing technology to identify minimal residual disease in lymphoid malignancies. Methods Mol Biol 2185:95–111 doi: 10.1007/978-1-0716-0810-4_7. [DOI] [PubMed]
  25. Stewart JP, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G et al (2021) EuroClonality-NGS Working Group. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Adv. 5(16):3188–3198. https://doi.org/10.1182/bloodadvances.2020004056.PMID:3442432 doi: 10.1182/bloodadvances.2020004056.PMID:3442432. [DOI] [PMC free article] [PubMed]

RESOURCES